Comparative Pharmacology
Head-to-head clinical analysis: HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX versus WESTADONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX versus WESTADONE.
HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX vs WESTADONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Chlorpheniramine is an antihistamine that competitively antagonizes histamine at H1 receptors, reducing allergic symptoms.
Mu-opioid receptor agonist; also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake.
Adults: 10 mL (hydrocodone polistirex 10 mg/chlorpheniramine polistirex 8 mg) orally every 12 hours; not to exceed 20 mL per day.
Oral: 2.5-10 mg every 4-6 hours as needed for pain; maximum 40 mg per day.
None Documented
None Documented
The terminal elimination half-life for hydrocodone from the polistirex formulation is approximately 3.8-4.5 hours in adults, with extended-release properties due to the polistirex complex. For chlorpheniramine polistirex, the half-life is about 20-24 hours, reflecting the prolonged release. These half-lives support twice-daily dosing in the extended-release formulation.
Terminal elimination half-life: 15-60 hours (mean ~24 hours). Clinical context: Prolonged half-life supports once-daily dosing in opioid maintenance; accumulation occurs with repeated dosing due to long half-life.
Hydrocodone polistirex and chlorpheniramine polistirex are excreted primarily renally. Hydrocodone and its metabolites are eliminated via kidneys (about 60-70% as unchanged drug and conjugates), with a small amount in feces (<10%). Chlorpheniramine is also predominantly renally excreted (30-50% unchanged, with metabolites). Biliary/fecal excretion accounts for less than 20% of total clearance for both components.
Primarily renal (40-50% as unchanged methadone and its metabolites, 15-20% as metadone-N-oxide), biliary/fecal (5-10%).
Category D/X
Category C
Opioid Agonist
Opioid Agonist